Ralf Ketter

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick, Michael Platten, Christoph Meisner et al. · The Lancet Oncology · 2012 · 1.1K citations · Full text

Neuro-oncology, Temozolomide Chemotherapy, Malignant Astrocytoma +9

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

Felix Sahm, Daniel Schrimpf, Damian Stichel et al. · The Lancet Oncology · 2017 · 814 citations · Full text

Chromatin, Mendelian Disorder, Dna Methylation-based Classification +12

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

Wolfgang Wick, Christian Hartmann, Corinna Engel et al. · Journal of Clinical Oncology · 2009 · 804 citations

TERT Promoter Mutations and Risk of Recurrence in Meningioma

Felix Sahm, Daniel Schrimpf, Adriana Olar et al. · JNCI Journal of the National Cancer Institute · 2015 · 393 citations · Full text

Prognostic Biomarkers, World Health Organization, Somatic Variant +14

<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner et al. · Clinical Cancer Research · 2015 · 311 citations · Full text